Question Is a multicomponent vaccine against seasonal influenza and SARS-CoV-2 (mRNA-1083) immunogenic and well-tolerated in adults 50 years and older?
Findings In this phase 3 study, mRNA-1083 elicited noninferior immune responses against standard care immunization: licensed standard-dose or high-dose seasonal influenza vaccine (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) coadministered with licensed SARS-CoV-2 (Omicron XBB.1.5) vaccine. The multicomponent vaccine mRNA-1083 had an acceptable tolerability and safety profile.
Meaning mRNA-1083 was demonstrated to be at least as immunogenic as recommended standard care vaccines against both seasonal influenza and COVID-19 and well-tolerated in adults 50 years and older.
This community is intended for healthcare professionals
As per the article
Being able to cite data about safety and effectiveness is helpful when making recommendations to patients, and necessary when healthcare professionals are discussing policy.
I included the results in the post body to make sure it wasn’t clickbait or misleading, but I’m always looking to improving it in the future if you have feedback